Results 71 to 80 of about 68,183 (284)

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

Bioactive Materials
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against ...
Yun Chang, Mingyang Chang, Xiaoping Bao, Cheng Dong   +3 more
doaj   +1 more source

Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system

Cancer Cell International, 2022
Immunotherapy has changed the treatment landscape for multiple cancer types. In the recent decade, great progress has been made in immunotherapy, including immune checkpoint inhibitors, adoptive T-cell therapy, and cancer vaccines. ICIs work by reversing
Yan Jin, Zhifeng Deng, Ting Zhu
doaj   +1 more source

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]

, 2004
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core   +1 more source

Ice Lithography: Recent Progress Opens a New Frontier of Opportunities

Advanced Functional Materials, EarlyView.
This review focuses on recent advancements in ice lithography, including breakthroughs in compatible precursors and substrates, processes and applications, hardware, and digital methods. Moreover, it offers a roadmap to uncover innovation opportunities for ice lithography in fields such as biological, nanoengineering and microsystems, biophysics and ...
Bingdong Chang, Gwendoline A. E. Anand, Rubaiyet Haque, Dylan A. Chiaro, Mona Sharma, Andrew R. Williams, Frank Niklaus, Daryl W. Yee, Gavin M. King, Anpan Han   +9 more
wiley   +1 more source

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

Journal of Translational Medicine, 2005
Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine ...
Yee Cassian
doaj   +1 more source

Expanding Chemical Space of Nucleic Acid Nanoparticles for Tunable Antiviral‐Like Immunomodulatory Responses and Potent Adjuvant Activity

Advanced Functional Materials, EarlyView.
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj, Hannah S. Newton, Jian Wang, Laxmi Pandey, Yelixza I. Avilla, Phong Nguyen, Morgan Chandler, Justin Halman, Yasmine Radwan, Stephanie Smith, Elijah Edmondson, Simone Difilippantonio, Chelsea Sanders, Bao Tran, Yongmei Zhao, Shaojun Xie, Edward Cedrone, Barry W. Neun, Meni Wanunu, Nikolay V. Dokholyan, Marina A. Dobrovolskaia, Kirill A. Afonin   +21 more
wiley   +1 more source

Clonal karyotype evolution involving ring chromosome 1 with myelodysplastic syndrome subtype RAEB-t progressing into acute leukemia [PDF]

, 2006
s Karyotypic evolution is a well-known phenomenon in patients with malignant hernatological disorders during disease progression. We describe a 50-year-old male patient who had originally presented with pancytopenia in October 1992.
Bennett JM, Bettina Wunderlich, Brigitte Poleck-Dehlin, Chen Z, Christoph Schmid, Cutler CS, De Witte T, Depil S, Georg Ledderose, Gisselsson D, Gullingsrud EO, Hans Jochen Kolb, Hebart H, Helga Schmetzer, Hoffmann WK, Hoffmeister PA, Holler E, Johann Mittermüller, Johansson B, Jotterand M, Kern W, Kolb HJ, Kolb HJ, Massenkeil G, Mattano, Mhawesch P, Mittermuller J, Moss PA, Mufti GJ, Rothe G, Sanders JE, Schmetzer H, Schmetzer H, Schmetzer HM, Schmid C, Seabright M, Seber A, Slovak ML, Sole F, Sole F, Thomas Duell, Tichelli A, Tichelli A, van Esser JW, Xu J, Yan J, Yoshida A   +46 more
core   +1 more source

Parameter estimation and treatment optimization in a stochastic model for immunotherapy of cancer [PDF]

, 2020
Adoptive Cell Transfer therapy of cancer is currently in full development and mathematical modeling is playing a critical role in this area. We study a stochastic model developed by Baar et al.
Coquille, Loren, Diabate, Modibo, Samson, Adeline   +2 more
core   +1 more source

PRELIVE: A Framework for Predicting Lipid Nanoparticles In Vivo Efficacy and Reducing Reliance on Animal Testing

Advanced Functional Materials, EarlyView.
PREdicting LNP In Vivo Efficacy (PRELIVE) framework enables the prediction of lipid nanoparticle (LNPs) organ‐specific delivery through dual modeling approaches. Composition‐based models using formulation parameters and protein corona‐based models using biological fingerprints both achieve high predictive accuracy across multiple organs.
Belal I. Hanafy, Chuan‐En Lu, Kai Liu, Audrey Gallud   +3 more
wiley   +1 more source

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Journal of Immunology Research, 2017
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells.
Baixin Ye, Creed M. Stary, Qingping Gao, Qiongyu Wang, Zhi Zeng, Zhihong Jian, Lijuan Gu, Xiaoxing Xiong   +7 more
doaj   +1 more source